Shire licenses TPC from Warren Pharma
UK drugmaker Shire says it has in-licensed rights to the Tissue Protective Cytokine Technology developed by Warren Pharmaceuticals of the USA. The deal affords the Basingstoke-headquartered firm exclusive, worldwide rights to develop TPC-based compounds in non-nervous system indications.
TPCs are modified forms of erythropoietin, the glycoprotein hormone that is administered to boost blood cell production and confer tissue protective effects in patients suffering chemotherapy-induced anemia. TPCs down-regulate the effect on red blood cell production, while retaining the protective impact, potentially reducing the rate of apoptosis as has been suggested in animal models.
Shire chief executive Matthew Emmens explained that the technology was an excellent strategic fit for the firm, in terms of both its human genetic therapy and renal disease drug development activities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze